Trial intelligence / Profile preview

Oral vs IV Magnesium for Emergence Delirium in Children Undergoing Adenotonsillectomy

NCT07655817Phase 3

Key facts

Status: Recruiting
Start: Jul 2026
Primary completion: Dec 2026
Countries: 1
Sponsor: Tanta University

Drugs: magnesium
Conditions: emergence delirium (ED)

Overview

Phase 3, randomised, double-blind trial of magnesium in emergence delirium (ED) (3 arms), sponsored by Tanta University. Primary endpoint: Incidence of emergence delirium. Started Jul 2026; status: recruiting.

Design

3 arms

Study design: RandomizedDouble-blind

Oral magnesium group
Preoperative oral magnesium dose of 150 mg at two hours before surgery.
Intravenous magnesium group
Intraoperative IV magnesium sulfate dose of 30 mg/kg over 10 minutes after induction of anesthesia.
Control group
Oral lemon juice at two hours before surgery and intraoperative IV saline over 10 minutes after induction of anesthesia.

Who it enrols

Children aged 4-7 years with ASA Status I or II planned for adenotonsillectomy under sevoflurane anesthesia, excluding those with psychiatric/neurological problems, taking sedatives/anticonvulsants, or having cardiovascular, renal, bone, or GI diseases.

Endpoints

Primary

Incidence of emergence deliriumUp to 1 hour after surgery

Secondary

Severity of emergence deliriumUp to 1 hour after surgery
Postoperative painUp to 1 hour after surgery
Parental separation anxietyPerioperative
Mask acceptancePerioperative
Total dose of rescue propofolUp to 1 hour after surgery
Total dose of rescue fentanylUp to 1 hour after surgery
Extubation timeEnd of surgery
Negative behavior changes24 hours after surgery

Beyond the preview

Go deeper on NCT07655817.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07655817.